Hyacinthe A. Ansah-Johnson

Caen, 14000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Journal: The Lancet. Haematology

Published: August 18, 2025

Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.

Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.

Journal: Leukemia

Published: April 28, 2025

Chimerism in blood after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: Results from a cohort study.

Chimerism in blood after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: Results from a cohort study.

Journal: Current research in translational medicine

Published: February 24, 2025

Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

Journal: Leukemia research

Published: February 05, 2025

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: April 07, 2023

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

Journal: Leukemia research

Published: December 21, 2022

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia.

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia.

Journal: Cancers

Published: September 14, 2022

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Journal: Pharmaceutics

Published: June 29, 2022

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Journal: British journal of haematology

Published: May 13, 2022

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.

Journal: Haematologica

Published: February 08, 2022

Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.

Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.

Journal: British journal of haematology

Published: August 16, 2021

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Journal: Leukemia

Published: January 24, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026